Luther King Capital Management (LKCM)’s Avanos Medical AVNS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-22,640
Closed -$544K 590
2024
Q3
$544K Buy
+22,640
New +$517K ﹤0.01% 461
2021
Q1
Sell
-4,870
Closed -$223K 553
2020
Q4
$223K Buy
+4,870
New +$203K ﹤0.01% 527
2020
Q3
Sell
-36,850
Closed -$1.08M 515
2020
Q2
$1.08M Sell
36,850
-930
-2% -$26.9K 0.01% 313
2020
Q1
$1.02M Sell
37,780
-1,690
-4% -$50.5K 0.01% 299
2019
Q4
$1.33M Sell
39,470
-905
-2% -$32.8K 0.01% 322
2019
Q3
$1.51M Sell
40,375
-1,350
-3% -$51.5K 0.01% 305
2019
Q2
$1.82M Buy
41,725
+810
+2% +$34.6K 0.01% 278
2019
Q1
$1.75M Buy
40,915
+16,945
+71% +$759K 0.01% 285
2018
Q4
$1.07M Sell
23,970
-5,425
-18% -$284K 0.01% 322
2018
Q3
$2.01M Buy
+29,395
New +$1.89M 0.02% 292
2015
Q2
Sell
-7,081
Closed -$348K 550
2015
Q1
$348K Sell
7,081
-56,107
-89% -$2.6M ﹤0.01% 462
2014
Q4
$2.87M Buy
+63,188
New +$2.48M 0.02% 291

Other funds holding AVNS

Luther King Capital Management (LKCM)'s AVNS Position: Q4 2024 in Review

Luther King Capital Management (LKCM) sold out of Avanos Medical (AVNS) in Q4 2024, closing a stake of 22,640 shares — an estimated $544K sold.

Luther King Capital Management (LKCM) first reported a position in AVNS in Q4 2014 and held it in 12 quarters. The position peaked at $2.87M in Q4 2014. 258 funds tracked by Wall St. Rank hold AVNS as of Q4 2024.

  • Luther King Capital Management (LKCM) reported no remaining Avanos Medical position as of Q4 2024 after selling out during the quarter.
  • Luther King Capital Management (LKCM) sold 22,640 Avanos Medical shares in Q4 2024, an estimated $544K.
  • Luther King Capital Management (LKCM) first reported a position in Avanos Medical in Q4 2014 and held it in 12 quarters.
  • Luther King Capital Management (LKCM)'s Avanos Medical position peaked at $2.87M in Q4 2014.
  • 258 funds tracked by Wall St. Rank held Avanos Medical as of Q4 2024.

Based on Luther King Capital Management (LKCM)'s 13F filing for Q4 2024, filed 7 Feb 2025.